Project Details
Description
DESCRIPTION: (Adapted from the Applicant's Abstract). Hepatitis B virus
(HBV) is a hepatotropic virus that is a major public health concern
worldwide. While a recombinant surface antigen vaccine is available,
there is no effective treatment for the millions of individuals who are
chronically infected. The objective of this proposal is to develop
peptide therapeutics that will generate cytotoxic T lymphocytes (CTL) in
vivo and may ameliorate chronic HBV infections. These molecules may also
be useful as prophylactic vaccines. This study aims to 1. define the
9-10 amino acids that constitute the core CTL epitopes; 2. modify these
peptides to enhance their stability, facilitate uptake into antigen
presenting cells and to enhance immunogenicity by adding helper epitopes;
3. to determine if these peptides can generate CTL's in vivo (in HLA-A2
transgenic mice).
Status | Finished |
---|---|
Effective start/end date | 4/1/92 → 4/30/97 |
Funding
- National Institute of Allergy and Infectious Diseases
ASJC
- Medicine(all)
- Immunology and Microbiology(all)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.